Menu

Find clinical trials for Asthma in Salt Lake City, UT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Allergic Rhinitis
Nasal Polyps
Rhinitis
Rhinosinusitis
Sinusitis
Conjunctivitis
A woman searches for clinical trials

Asthma trials near Salt Lake City, UT, USA:

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Placebo
Drug: Dexpramipexole Dihydrochloride

Phase 3

Areteia Therapeutics

Salt Lake City, Utah, United States and 331 other locations

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will e...

Enrolling
Severe Asthma
Drug: Placebo
Drug: Verekitug (UPB-101)

Phase 2

Upstream Bio

West Jordan, Utah, United States and 147 other locations

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma...

Active, not recruiting
Asthma Attack
Asthma; Eosinophilic
Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

Phase 3

Areteia Therapeutics

Murray, Utah, United States and 314 other locations

is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma...

Enrolling
Asthma
Asthma; Eosinophilic
Drug: Dexpramipexole Dihydrochloride
Drug: Placebo

Phase 3

Areteia Therapeutics

Pleasant View, Utah, United States and 247 other locations

The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed repl....

Enrolling
Asthma
Drug: BDA MDI HFO 160/180 μg
Drug: BDA MDI HFA 160/180 μg

Phase 3

AstraZeneca
AstraZeneca

West Jordan, Utah, United States and 134 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Active, not recruiting
Asthma
Biological: GSK3511294 (Depemokimab)
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Murray, Utah, United States and 397 other locations

administered via a dry powder inhaler in adults with uncontrolled asthma at risk of exacerbations, receiving medium -to -high dose inhaled c...

Enrolling
Asthma
Device: Inhaler
Drug: AZD8630

Phase 2

AstraZeneca
AstraZeneca

Salt Lake City, Utah, United States and 229 other locations

Locations recently updated

The primary objective of the trial is to evaluate the efficacy of fluticasone propionate/albuterol sulfate multidose dry powder inhaler with electron...

Enrolling
Asthma
Drug: Placebo
Drug: FP

Phase 3

Teva Pharmaceuticals
Teva Pharmaceuticals

Salt Lake City, Utah, United States and 42 other locations

Locations recently updated

inhaler (eMDPI) compared to ABS eMDPI in decreasing severe clinical asthma exacerbation (CAEs).Secondary Objectives:To evaluate the efficacy...

Enrolling
Asthma
Drug: Albuterol sulfate
Drug: TEV-56248

Phase 3

Teva Pharmaceuticals
Teva Pharmaceuticals

Bountiful, Utah, United States and 362 other locations

MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis...

Enrolling
Asthma
Combination Product: BDA MDI
Combination Product: AS MDI

Phase 3

AstraZeneca
AstraZeneca

West Jordan, Utah, United States and 106 other locations